Lipoedema is a chronic disorder of adipose tissue characterised by disproportionate fat distribution, tissue tenderness and altered fat behaviour, most commonly affecting the hips, buttocks, thighs and sometimes the arms. The condition occurs almost exclusively in women and appears to be influenced by hormonal and genetic susceptibility, although its precise biological mechanisms remain uncertain.
Unlike many medical diseases, lipoedema does not currently have a definitive diagnostic test. There are no validated biomarkers, no specific histological markers and no genetic test that can confirm the condition. Diagnosis therefore relies on clinical assessment, pattern recognition and the exclusion of other conditions such as obesity, lymphoedema and venous disease. This makes lipoedema a challenging diagnosis and helps explain why many women live with symptoms for years before receiving a clear explanation.
Rather than being defined by overall body weight, like obesity, lipoedema is defined by pattern and distribution of adipose tissue. Individuals typically develop a noticeable disproportion between the upper and lower body, with the lower body enlarging symmetrically while the feet and hands remain relatively unaffected.
This relative sparing of the feet and hands often produces a visible cuff at the ankles or wrists. The symmetrical pattern of fat accumulation is one of the key features clinicians recognise when considering the diagnosis.
The adipose tissue involved in lipoedema may feel nodular or tender and many individuals report aching, heaviness or easy bruising in the affected areas. The fat is often described as stubborn, meaning that body proportions frequently remain even when overall body weight reduces. However, this does not mean that fat cannot respond to metabolic change. People with lipoedema can lose weight through dietary change and physical activity, but the characteristic lower-body disproportion may remain. Lipoedema is also not progressive in the true nature of the word; if body weight remains stable, the disease does not progress on its own.
Lipoedema most commonly becomes noticeable during times of hormonal transition. Puberty is the most frequently reported onset, although symptoms may also emerge or worsen during pregnancy or around menopause.
This timing strongly suggests that hormonal signalling, particularly involving oestrogen, plays a role in the development of the condition. The overwhelming predominance in women supports this observation.
Cases in men are extremely rare and are usually associated with significant endocrine disturbance such as hypogonadism or other disorders affecting sex hormone balance.
Family history is frequently reported among those with lipoedema. Many women recognise similar body shapes or symptoms in mothers, grandmothers or other relatives.
Susceptibility may appear through either the maternal or paternal bloodline, suggesting that inheritance may involve multiple genes rather than a simple single-gene pattern. However, it is important to emphasise that no genetic test currently exists that can diagnose lipoedema, and research into genetic mechanisms remains ongoing.
One of the major challenges in lipoedema is that no laboratory or imaging test can currently confirm the diagnosis.
There are:
Diagnosis therefore relies on clinical assessment, based on the pattern of fat distribution, reported symptoms, medical history and physical examination.
Clinicians must also exclude other conditions that may cause swelling or adipose enlargement, including obesity, lymphoedema, venous disease and other adipose tissue disorders. This reliance on clinical assessment means that diagnosis can be difficult and may vary between practitioners.
Another observation increasingly recognised in clinical populations is the overlap between lipoedema and disorders involving connective tissue and autonomic regulation.
Many individuals with lipoedema report hypermobility or are diagnosed with other conditions such as:
These conditions share features involving connective tissue integrity, immune signalling and autonomic nervous system regulation. Although these relationships remain associative rather than causal, they are frequently observed in clinical practice.
Several clinical studies have reported that lipoedema frequently co-exists with a range of other medical conditions, particularly those involving connective tissue, hormonal regulation and chronic inflammatory processes. A large Spanish cohort study published in December 2025 examined more than 1,800 patients with clinically diagnosed lipoedema and found a high prevalence of associated systemic conditions.
Connective tissue features such as ligamentous hyperlaxity were extremely common, alongside chronic pain syndromes affecting structures such as the iliotibial band and the greater trochanteric region.
The study also reported frequent endocrine and gynaecological conditions, including thyroid disorders and inflammatory ovarian dysfunction, together with menstrual irregularities and other uterine-related symptoms.
Psychological conditions such as anxiety and depression were also commonly reported, reflecting the complex clinical burden associated with the disorder.
More broadly, other clinical cohorts and reviews have described increased reporting of conditions such as endometriosis, polycystic ovary syndrome, uterine fibroids and thyroid dysfunction in people with lipoedema.
These patterns reinforce the observation that the condition often sits alongside a wider network of hormonal, connective tissue and inflammatory disorders, rather than existing as an isolated adipose tissue disease.
While these associations are increasingly recognised in clinical populations, current evidence remains largely observational, and further research is needed to determine whether these relationships represent shared underlying biological mechanisms or simply reflect overlapping populations.
Lipoedema is often confused with obesity, yet the two conditions are not the same.
Obesity reflects a generalised increase in body fat influenced largely by energy balance and metabolic factors. Lipoedema, by contrast, involves a regional and symmetrical deposition of adipose tissue, typically affecting the lower body.
The two conditions can coexist and frequently do, particularly when overall body weight increases. However, recognising the difference between generalised adiposity and disproportionate adipose deposition is important for understanding the condition and guiding management strategies.
Historically, lipoedema has been divided into stages based on changes in skin texture and tissue appearance.
In practice, these staging systems have proved inconsistent and often do not reflect the complexity of the condition. Patients do not necessarily progress through stages in a predictable way, and staging categories rarely determine treatment choices.
For this reason, many clinicians now focus instead on symptoms, functional impact, metabolic health and associated conditions, rather than relying heavily on traditional staging systems.
Management usually begins with conservative approaches aimed at improving symptoms and supporting tissue health.
Compression therapy is widely used to support venous and lymphatic circulation and may reduce heaviness or discomfort in the limbs. Regular movement and exercise are also important, particularly activities that support muscle pump function and overall metabolic health.
Manual therapies are often included in supportive care. Techniques such as manual lymphatic drainage, myofascial release and other soft-tissue therapies may help improve tissue mobility, reduce discomfort and support fluid movement in some cases.
Dietary approaches are frequently discussed. Although there is no single diet proven to treat lipoedema, some women report improvement with dietary changes aimed at stabilising metabolism or reducing inflammatory load. These may include ketogenic, low-carbohydrate and low-histamine diets or broader anti-inflammatory nutritional eating.
Surgical treatment may be considered for selected patients, most commonly through liposuction techniques used to reduce adipose volume.
These procedures remove the affected fat tissue and may improve mobility, pain and body proportions in some cases. However, liposuction is an invasive intervention that mechanically disrupts subcutaneous tissue and can cause injury to lymphatic vessels. For this reason, careful patient selection and realistic expectations are essential.
Recognition of lipoedema remains sporadic across healthcare systems. Many individuals report years of denial and uncertainty before encountering clinicians familiar with the condition.
Improving awareness among clinicians and researchers is helping to expand understanding of adipose tissue disorders and their relationships with connective tissue biology, hormonal regulation and systemic inflammation.
Lipoedema is a complex condition involving fat distribution, hormonal influences, connective tissue characteristics and systemic physiology. It is diagnosed clinically because there are currently no biomarkers, histological markers or genetic tests capable of confirming the condition, as yet.
Although many aspects of its biology remain uncertain, growing research is helping to clarify the condition and improve approaches to care. Continued scientific investigation will be essential to improve diagnostic clarity and develop more effective treatments.
Al-Ghadban S., Cromer W., Allen M., Ussery C., Badowski M., Harris D., Herbst K. (2019) Dilated blood and lymphatic microvessels, angiogenesis and lymphangiogenesis in lipedema adipose tissue. Angiogenesis, 22(1), 87–99.
Child A., Gordon K., Sharpe P., Brice G., Ostergaard P., Jeffery S., Mortimer P. (2010) Lipedema: an inherited condition. American Journal of Medical Genetics Part A, 152A(4), 970–976.
Forner-Cordero I., Szolnoky G., Forner-Cordero A., Kemény L. (2012) Lipedema: an overview of its clinical manifestations, diagnosis and treatment. Journal of the European Academy of Dermatology and Venereology, 26(3), 273–278.
Halk A., Damstra R. (2017) First Dutch guidelines on lipedema using the international classification of functioning, disability and health. Phlebology, 32(3), 152–159.
Herbst K., Kahn L., Iker E., Ehrlich C., Wright T., McDonnell M. (2021) Standard of care for lipedema in the United States. Phlebology, 36(10), 779–796.
Langendoen S., Habbema L., Nijsten T., Neumann M. (2009) Lipedema: from clinical presentation to therapy. Dermatologic Surgery, 35(1), 1–8.
Simarro Blasco, J.L., Michelini, S., Andrés-Gasco, M., Lebrero García, A., Ortega Abad, D., Margalejo Lombardo, J., Buj Vargas, J., Sánchez-Costa, J.T. & Martín Martínez, M.A. (2025) Clinical signs at diagnosis and comorbidities in a large cohort of patients with lipedema in Spain. Biomedicines, 13(12), 3049. https://doi.org/10.3390/biomedicines13123049.
Sandhofer M., Hanke C., Habbema L. (2020) Prevention of progression of lipedema with liposuction. Phlebology, 35(9), 664–673.
Wold L., Hines E., Allen E. (1951) Lipedema of the legs: a syndrome characterised by fat legs and orthostatic edema. Annals of Internal Medicine, 34(5), 1243–1250.
